Detalhe da pesquisa
1.
Evaluation of pregnancy outcomes from the Tysabri® (natalizumab) pregnancy exposure registry: a global, observational, follow-up study.
BMC Neurol
; 16(1): 150, 2016 Aug 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-27552976
2.
Risk of natalizumab-associated progressive multifocal leukoencephalopathy.
N Engl J Med
; 366(20): 1870-80, 2012 May 17.
Artigo
em Inglês
| MEDLINE | ID: mdl-22591293
3.
Predictors of survival and functional outcomes in natalizumab-associated progressive multifocal leukoencephalopathy.
J Neurovirol
; 21(6): 637-44, 2015 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-25771865
4.
Anti-JC virus antibody levels in serum or plasma further define risk of natalizumab-associated progressive multifocal leukoencephalopathy.
Ann Neurol
; 76(6): 802-12, 2014 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-25273271
5.
Anti-John Cunnigham virus antibody prevalence in multiple sclerosis patients: baseline results of STRATIFY-1.
Ann Neurol
; 70(5): 742-50, 2011 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-22162056
6.
Risk of natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: a retrospective analysis of data from four clinical studies.
Lancet Neurol
; 16(11): 925-933, 2017 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-28969984
7.
Outcome and survival of asymptomatic PML in natalizumab-treated MS patients.
Ann Clin Transl Neurol
; 1(10): 755-64, 2014 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-25493267
8.
A novel PEGylated interferon beta-1a for multiple sclerosis: safety, pharmacology, and biology.
J Clin Pharmacol
; 52(6): 798-808, 2012 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-21680782
9.
PEGylated interferon beta-1a: meeting an unmet medical need in the treatment of relapsing multiple sclerosis.
J Interferon Cytokine Res
; 30(10): 777-85, 2010 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-20836711